Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Placebo-controlled, Multi-center Study to Evaluate Safety and Efficacy of Recombinant Human Thrombopoietin Among Severe Sepsis Patients With Thrombocytopenia

NCT02094248 is registered in ClinicalTrials.gov with Jinling Hospital, China as lead sponsor.

NCT NCT02094248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02094248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Placebo-controlled, Multi-center Study to Evaluate Safety and Efficacy of Recombinant Human Thrombopoietin Among Severe Sepsis Patients With Thrombocytopenia
Lead sponsor
Jinling Hospital, China
Phase
Phase 2/3
Overall status
Unknown status
Start date
March 31, 2014
Completion date
April 30, 2016
Enrollment
600 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sepsis, thrombocytopenia